'Intermittent Dosing' Strategy In Lab Mice Suggests Simple Way To Help People With Late-Stage Melanoma

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease. The team, based at the University of California, San Francisco (UCSF), the Novartis Institutes for Biomedical Research (NIBR) in Emeryville, Calif...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/Sy4uWZo7p0o/254768.php

sport medical sport news news